Merck's Calderasib and Durvalumab Trial for KRAS G12C NSCLC Enters Phase
A clinical trial is investigating the combination of calderasib (MK-1084) and durvalumab in patients with unresected KRAS G12C-mutated NSCLC.
Phase III
Oncology / NSCLC
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Success in this trial may enhance Merck's portfolio in NSCLC and provide a competitive edge against other therapies targeting KRAS mutations.
Why it matters
The ongoing clinical trial of Calderasib and Durvalumab represents a significant opportunity for Merck to strengthen its position in the competitive NSCLC landscape, particularly for patients with KRAS mutations. Success in this trial could enhance Merck's portfolio and market share in a rapidly evolving therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety, particularly overall survival and progression-free survival metrics.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.